| Abstract |
[Abstract] Objective: To explore the effect of HP conversion and the influence of symptom score in patients with hP-related chronic gastritis complicated with depression treated by doxepin combined with quadruple therapy. Methods: A total of 80 patients with helicobacter pylori (HP) associated chronic gastritis and depression admitted to our hospital from March 2017 to March 2020 were retrospectively selected as study subjects, and were divided into control group and observation group, 40 cases each according to different treatment plans. The control group was treated with quadruple therapy, and the observation group was treated with doxepin in addition to the control group. At the end of January, clinical efficacy, negative emotions, levels of gastrointestinal hormones and inflammatory factors, HP clearance rate and drug safety were compared between the two groups. Results: The total effective rate of the observation group was 90.00% (36/40) higher than that of the control group (67.50% (27/40) (P<0.05). The haDS-A and HADS-D scores in both groups at the end of January were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). The serum levels of GAS, CRP and IL-6 in both groups at the end of January were lower than those before treatment, and those in the observation group were lower than those in the control group. Serum SS levels were higher in the observation group than in the control group (P<0.05). The HP clearance rate of observation group was 95.00% (38/40) higher than that of control group (75.00% (30/40) (P<0.05). The total adverse reaction rate in the observation group was 7.50% (3/40) higher than that in the control group (2.50% (1/40), and the difference was not statistically significant (P>0.05). Conclusion: Doxepin combined with quadruple therapy in the treatment of HP-related chronic gastritis improves gastrointestinal hormone levels by reducing irritation to gastric mucosa, regulating inflammatory factor indicators, improving symptoms such as abdominal discomfort and abdominal distension, adjusting patients state of mind, reducing rash, dizziness and other adverse reactions, and improving clinical efficacy.
|